Ginkgo Results Presentation Deck
New partnership with Aldevron has potential to generate
substantial near-term royalties
mRNA Supply Chain is Expanding
for
Moderna and Pfizer/BioNTech have paved the way
future mRNA therapeutic growth
Modality yields faster time to market and strong
performance
Pfizer + Moderna are expected to produce 4-6 billion
doses annually for COVID-19
●
●
Large pipeline of population-scale mRNA vaccines in
development (e.g. COVID boosters, flu)
mRNA supply chain requires investment
Prior to COVID, mRNA modality was experimental and
generally being directed to relatively rare diseases
Several key components (pDNA, processing enzymes,
even freezers, etc.) have become bottlenecked
●
Aldevron collaboration dramatically improves availability
and cost of Vaccinia Capping Enzyme (VCE), enabling it
to be used in support of more therapies and doses
New COVID Vaccines Need Absurd Amounts
of Material and Labor
SCIENTIFIC
AMERICAN
MEDICINE
Companies are scrambling to obtain supplies for hundreds of millions of
doses of a type of vaccine that has never been made at this scale before
By Charles Schmidt on January 4, 2021
Partner
(signed 2021)
Program Goals
CASE STUDY 2
aldevron
Progress to Date
Collaboration in Brief
Aldevron, a leading manufacturer of nucleic acids and
proteins, serving the biotechnology industry. Recently
announced pending acquisition by Danaher for $9.5Bn.
Engineer organism and create new manufacturing process to
improve production volumes and cost of Vaccinia Capping
Enzyme (VCE), a key reagent for certain mRNA vaccines
Completed program and yielded >10x improvement in
process, Aldevron is in the market with novel product
H1 UPDATE | AUGUST 2021
GINKGO BIOWORKS
19View entire presentation